Table 2.
Author, year | Number of patients | Regimena | Molecular target | PFSb (median) | OSc (median) |
---|---|---|---|---|---|
GOG 181 B [11] | 67 | Trastuzumab | Her-2/neu | 2 | |
GOG 188 | Faslodex | ||||
GOG 238 | WPI ± concurrent | ||||
CDDP | |||||
GOG 248 | Temsirolimus | mTOR, PTEN | |||
GOG 229 Series | |||||
B [12] | 27 | Thalidomide | 1.9 | 8.3 | |
C[13] | 29 | Gefitinib | EGFR | 4/26 pts PFS | N/A |
>6 months | |||||
D | 31 | Lapatinib | EGFR | ||
E [14] | 56 | Bevacizumab | VEGF | 1.7 | 6.3 |
F | 28 | VEGF-TRAP | |||
G | 29 | Bevacizumab + | |||
Temsirolimus | |||||
GOG 129 Series | |||||
N [15] | Docetaxel | 3 | 10.6 | ||
O [16] | 27 | Pemetrexed | 2.7 | 9.4 | |
P [17] | 52 | Ixabepilone | Epothilone B | 2.9 | 8.7 |
Q | Gemcitabine |
WPI = whole pelvic irradiation.
Progression free survival.
Overall survival.